share_log

Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August

Defense World ·  Aug 26, 2022 13:21

Medicure Inc. (OTCMKTS:MCUJF – Get Rating) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 100 shares, a decline of 66.7% from the July 31st total of 300 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is presently 0.0 days.

Medicure Trading Down 6.2 %

Shares of MCUJF stock opened at $0.79 on Friday. The company's fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $0.84. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.61 and a quick ratio of 1.18. Medicure has a 1 year low of $0.64 and a 1 year high of $1.10. The stock has a market capitalization of $8.10 million, a price-to-earnings ratio of 14.04 and a beta of 0.83.

Get Medicure alerts:

Medicure (OTCMKTS:MCUJF – Get Rating) last issued its earnings results on Monday, May 30th. The company reported $0.04 earnings per share (EPS) for the quarter. Medicure had a net margin of 3.40% and a return on equity of 4.28%. The business had revenue of $4.51 million for the quarter.

About Medicure

(Get Rating)

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.

Featured Articles

  • Get a free copy of the StockNews.com research report on Medicure (MCUJF)
  • Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
  • Is PayPal A Buy After Post-Earnings Price Jump?
  • Williams-Sonoma's High-End Consumers Are Still Spending
  • Snowflake Stock Soars On Strong Results
  • ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment